Published in Int J Cardiol on July 16, 2012
Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet (2013) 3.30
The Genetic Challenges and Opportunities in Advanced Heart Failure. Can J Cardiol (2015) 0.77
Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation. Arq Bras Cardiol (2015) 0.77
Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy. Int J Med Sci (2016) 0.75
Hypertension in adult Fabry's disease: is cardiotrophin-1 a diagnostic biomarker? Immun Ageing (2014) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Intensive insulin therapy in the medical ICU. N Engl J Med (2006) 22.37
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62
The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87
Acute renal failure. Lancet (2005) 5.60
Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet (2010) 3.36
Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis (2009) 3.33
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol (2014) 3.06
Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med (2013) 2.96
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet (2006) 2.94
Management of crush-related injuries after disasters. N Engl J Med (2006) 2.90
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol (2008) 2.76
Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Acute kidney injury: an increasing global concern. Lancet (2013) 2.61
Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest (2005) 2.61
Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant (2012) 2.59
Acute kidney injury. Lancet (2008) 2.44
Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med (2012) 2.39
The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrol Dial Transplant (2005) 2.38
Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant (2012) 2.27
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med (2006) 2.22
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrol Dial Transplant (2006) 2.17
Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. Hypertension (2005) 2.15
Cytomegalovirus serostatus and outcome in nonimmunocompromised critically ill patients. Crit Care Med (2012) 2.14
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant (2014) 2.10
Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant (2009) 2.06
A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med (2012) 2.06
The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol (2006) 2.01
Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol (2012) 1.98
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int (2009) 1.93
Chronic kidney disease in adults--UK guidelines for identification, management and referral. Nephrol Dial Transplant (2006) 1.91
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2013) 1.90
Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol (2012) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int (2004) 1.83
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis (2007) 1.83
Clinical review: What is the role for autopsy in the ICU? Crit Care (2010) 1.79
Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis (2007) 1.77
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int (2013) 1.68
Cardiovascular manifestations in men and women carrying a FBN1 mutation. Eur Heart J (2010) 1.68
The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol (2005) 1.67
Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics (2009) 1.67
EBPG guideline on haemodynamic instability. Nephrol Dial Transplant (2007) 1.65
Why less success of the peritoneal dialysis programmes in Europe? Nephrol Dial Transplant (2008) 1.65
Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet (2012) 1.62
Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrol Dial Transplant (2002) 1.60
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis (2004) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer (2009) 1.56
P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant (2006) 1.53
Severity of sepsis-induced acute kidney injury in a novel mouse model is age dependent. Crit Care Med (2012) 1.52
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J Nephrol (2005) 1.51
Catheter-related blood stream infections (CRBSI): a European view. Nephrol Dial Transplant (2010) 1.50
Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients. Crit Care Med (2008) 1.49
Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol (2006) 1.49
Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int (2008) 1.49
Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: mission impossible? Transplantation (2008) 1.49
The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int (2014) 1.48
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood (2003) 1.47
Acute renal failure due to crush syndrome during Marmara earthquake. Am J Kidney Dis (2002) 1.47
Echocardiographically estimated left ventricular end-diastolic and right ventricular systolic pressure in normotensive healthy individuals. Int J Cardiovasc Imaging (2006) 1.42
Initiation of dialysis--is the problem solved by NECOSAD? Nephrol Dial Transplant (2002) 1.42
Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD. Int J Cardiol (2011) 1.41
Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol (2010) 1.40
European Renal Best Practice (ERBP) Guideline development methodology: towards the best possible guidelines. Nephrol Dial Transplant (2013) 1.40
Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms. Clin Chem (2008) 1.39
The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J (2007) 1.38
Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int (2009) 1.34
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant (2010) 1.34
The gut: the forgotten organ in uremia? Blood Purif (2010) 1.33
When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant (2011) 1.30